TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02931149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Submucosal injection with PRP was performed prior to endoscopic resection
Study: NCT01672762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study: NCT02731521

Intervention type: DEVICE
Intervention: 3 Tesla Scanning
Description: Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.

Intervention type: DEVICE
Intervention: 7 Tesla Scanning
Description: Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
Study: NCT03458897

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serial functional magnetic resonance imaging (MRI)
Description: All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
Study: NCT03486743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video on LARC
Description: Participants will watch a short educational video on long acting reversible contraceptive or LARC
Study: NCT02022462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigation
Description: Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Navigation
Description: Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention.
Study: NCT03107702

Intervention type: DIAGNOSTIC_TEST
Intervention: melatonin
Description: the relationship between melatonin level and analgesia requirement.
Study: NCT00182520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25 mg - 400 mg/day x 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 25 - 400 mg/day x 12 weeks
Study: NCT01571921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction
Description: Single oral TRF or Gamma-Delta Tocotrienol dosage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction
Description: Single oral TRF or Gamma-Delta Tocotrienol dosage
Study: NCT03688828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 500mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1.0g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1.0g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.22g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.22g bid
Study: NCT03564691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
Study: NCT03570892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Description: Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
Study: NCT03983343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: exofin®
Description: Perineal skin will be closed by adhesive glue - exofin® (Octyl-2-cyanoacrylate).
Study: NCT03690856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inflammatory, neuropsychological and neuroimaging assessment
Description: Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)
Study: NCT03813056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glanatec
Description: Rho kinase Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive, Ophthalmic Solution
Description: artificial tears (placebo)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
Study: NCT04399707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) unit
Description: Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation (TENS) unit
Description: Patients will be randomized to active TENS unit, placebo TENS unit, or no TENS unit
Study: NCT00552734

Intervention type: DEVICE
Intervention: Insulin Guidance Software
Description: At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.

Intervention type: DEVICE
Intervention: Insulin Guidance Software
Description: At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
Study: NCT03794804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ColdZyme
Description: ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ColdZyme Placebo
Description: The placebo mouth spray solution has the following composition: ethanol (\<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
Study: NCT00507208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint Trismus System
Description: The Dynasplint System will be used for 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Depressors
Description: Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
Study: NCT02786927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 1
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 2
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 2
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
Study: NCT02608424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)
Description: The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
Study: NCT03481855

Intervention type: DEVICE
Intervention: Lower-body-low-pressure chamber
Description: The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.

Intervention type: DEVICE
Intervention: Lower-body-low-pressure chamber
Description: The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
Study: NCT01436643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
Study: NCT02296957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosedative discontinuation
Description: Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
Study: NCT05179161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone crawl positioning
Description: Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
Study: NCT02124473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01023919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Cypher stent or YinYi stent randomly implanted in coronary artery disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Cypher stent or YinYi stent randomly implanted in coronary artery disease
Study: NCT03697733

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fractional curettage
Description: Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional curettage
Description: Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
Study: NCT03564691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.
Study: NCT02862327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexamethasone
Description: intravenous injection of dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous placebo
Description: intravenous injection of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: perineural ropivacaine
Description: brachial plexus block with perineural injection of Ropivacaine in the axillary fossa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: perineural ropivacaine
Description: brachial plexus block with perineural injection of Ropivacaine in the axillary fossa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guidance
Description: ultrasound guidance for brachial plexus block in the axillary fossa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guidance
Description: ultrasound guidance for brachial plexus block in the axillary fossa
Study: NCT04582877

Intervention type: DEVICE
Group type: OTHER
Intervention: FFR measurement
Description: FFR is measured sequentially with the test article and the predicate device.
Study: NCT01328587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
Study: NCT05173571

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive patient support program (educational, physiotherapy, nutritional, emotional)
Description: Identification of patient needs and non-pharmacological holistic approach, including education, emotion and nutrition (nurse) and optimization of physical activity (respiratory physiotherapist)
Study: NCT03564691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.
Study: NCT03530553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hunt Motivational Scale
Description: The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
Study: NCT03564691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV Q3W.
Study: NCT04969822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iDAScore®
Description: A system that studies time lapse images obtained from the embryo culture system, Embryoscope, throughout the development to blastocyst. The system uses data acquired from a sequence of embryo images and has taught itself to identify the embryos with the highest likelihood of implanting and leading to fetal heart-beat detection.
Study: NCT03639441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study: NCT03936829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.